Sarcopenia - the gradual loss of muscle mass and strength with age - is one of the central problems of longevity. By age 80, the average person loses 30-50% of the muscle mass they had at age 30. While European and American studies have identified dozens of genes linked to risk, researchers in Korea have pointed out something new: much of what works in Western populations is not relevant to Asians. They now present 4 different genes that explain the differences.
Why Ethnic Genetics Matters
Sarcopenia is a common phenomenon worldwide, but statistics reveal interesting differences:
- In Korea: 13% of the population over 65 suffers from sarcopenia.
- In Japan: 9-15%, depending on the diagnostic criteria.
- In the USA: 14% of seniors over 65, but the criteria differ.
Part of the difference is diet and physical activity. But the Asian researchers noticed something else: genes identified in Western studies, such as certain variants of ACTN3 or FNDC5, did not show the same effects in Asian populations. Why?
The Study: GWAS on 7,500 Patients
The Korean team, from Seoul University Hospital, recruited 7,521 patients over age 60 for a full genetic review. They were divided into groups:
- Confirmed sarcopenia (loss of muscle mass + hand grip strength below Asian criteria).
- Incipient sarcopenia (only one of the criteria).
- Healthy control group.
All participants underwent SNP genotyping for approximately 700,000 different variants, and a GWAS (Genome-Wide Association Study) analysis compared the frequency of each variant between the groups.
The Findings: 4 Genes Not Seen in the West
After stringent statistical corrections, 4 genes emerged showing a significant association with sarcopenia - three of which were not reported in previous Western studies:
- Gene 1 - ACTN3 (Asian variant): Encodes the actinin-3 protein in muscles. The "Western" variant R577X has been known for a long time, but the Korean team found a second variant in the same gene that is frequent only in Asia and affects muscle mass differently.
- Gene 2 - GHR (Growth Hormone Receptor): A variant that reduces muscle sensitivity to growth hormone. In Koreans, this variant was found in 23% of sarcopenia patients compared to 11% in healthy individuals.
- Gene 3 - Completely new: A variant on chromosome 7 near genes involved in muscle protein synthesis (mTOR pathway).
- Gene 4 - Completely new: A variant on chromosome 11 related to mitochondrial function in muscle.
Why This Matters
For years, genetic studies on sarcopenia were mostly based on European and white American populations. The Korean finding illuminates three important truths:
- Variant frequency differs significantly between ethnicities. A variant that "does not exist" in one population can be common in another.
- Gene-diet interaction depends on local food. An Asian diet rich in rice and low in calcium expresses certain genes differently than a Western diet.
- Drugs targeting these genes may be more effective in certain populations.
Clinical Implications
The researchers propose a new protocol for sarcopenia risk screening in Asian populations:
- Testing SNPs in the four identified genes, starting at age 50.
- Ethnicity-adjusted risk assessment.
- Early intervention for high-risk individuals: protein-rich diet, resistance training, possibly creatine supplements.
- In prominent cases: considering growth hormone supplements (under medical supervision).
The Broader Message
This study is an example of a broader phenomenon in personalized medicine: genetics is not universal. This finding connects to a series of studies in recent years showing that:
- APOE variants linked to Alzheimer's vary between populations.
- Drug metabolism genes (CYP) require different dosages in different ethnicities.
- Genetic risk for type 2 diabetes differs dramatically between Westerners, Asians, and Africans.
If science is to fulfill its promise of personalized medicine in the anti-aging era, it will need to work with diverse populations, not just those participating in studies. This Korean step is part of that correction.
References:
Korea Biomedical Review
💬 תגובות (0)
היו הראשונים להגיב על המאמר.